Benitec Biopharma (BNTC) Expected to Announce Earnings on Monday

Benitec Biopharma (NASDAQ:BNTC) is expected to be posting its quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Benitec Biopharma to post earnings of ($0.36) per share for the quarter.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.19. On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Benitec Biopharma Trading Up 0.1 %

BNTC opened at $13.75 on Friday. The stock’s fifty day simple moving average is $13.61 and its 200 day simple moving average is $11.93. The stock has a market cap of $322.45 million, a PE ratio of -9.11 and a beta of 0.34. Benitec Biopharma has a 1-year low of $5.74 and a 1-year high of $16.90.

Insiders Place Their Bets

In other news, Director Suvretta Capital Management, L acquired 900,000 shares of Benitec Biopharma stock in a transaction dated Wednesday, March 26th. The shares were bought at an average cost of $13.00 per share, with a total value of $11,700,000.00. Following the purchase, the director now owns 8,793,245 shares in the company, valued at $114,312,185. This trade represents a 11.40 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

BNTC has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of Benitec Biopharma in a report on Monday, March 24th. JMP Securities lifted their price objective on shares of Benitec Biopharma from $18.00 to $20.00 and gave the company a “market outperform” rating in a research note on Thursday, April 10th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $24.71.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.